Details of the Drug

General Information of Drug (ID: DM5L6HI)

Drug Name

Atomoxetine

Synonyms

Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]
Methamphetamine dependence	6C46.2	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

255.35

Logarithm of the Partition Coefficient (xlogp)

3.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 350 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 63% [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 9.3 mL/min/kg [5]
Elimination: Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose) []
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 5.6 hours [3]
Metabolism: The drug is metabolized via several other cytochrome P450 enzymes []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.3915 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [5]
Vd: The volume of distribution (Vd) of drug is 1.6-2.6 L/kg [3]
Water Solubility: The ability of drug to dissolve in water is measured as 27.8 mg/mL [4]

Chemical Identifiers

Formula: C17H21NO
IUPAC Name: (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
Canonical SMILES: CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
InChI: InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
InChIKey: VHGCDTVCOLNTBX-QGZVFWFLSA-N

Cross-matching ID

PubChem CID: 54841
ChEBI ID: CHEBI:127342
CAS Number: 83015-26-3
DrugBank ID: DB00289
TTD ID: D04CRN
VARIDT ID: DR00393
INTEDE ID: DR0153
ACDINA ID: D00049

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Attention deficit hyperactivity disorder

ICD Disease Classification

6A05.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Norepinephrine transporter (NET)	DTT	SLC6A2	7.05E-01	7.02E-03	0.07
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.83E-01	4.69E-02	1.89E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	7.66E-01	9.19E-03	4.88E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Atomoxetine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[10]
-----------

Coadministration of a Drug Treating the Disease Different from Atomoxetine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[11]
Methylene blue	DMJAPE7	Major	Increased risk of hyperpyrexia by the combination of Atomoxetine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[12]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Thioguanine.	Acute myeloid leukaemia [2A60]	[13]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Midostaurin.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Arn-509.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Oliceridine.	Acute pain [MG31]	[15]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Galantamine.	Alzheimer disease [8A20]	[15]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Rivastigmine.	Alzheimer disease [8A20]	[15]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Donepezil.	Alzheimer disease [8A20]	[15]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Atomoxetine and Metronidazole.	Amoebiasis [1A36]	[11]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Ivabradine.	Angina pectoris [BA40]	[10]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Dronedarone.	Angina pectoris [BA40]	[15]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[15]
Clobazam - Lundbeck	DMW1OQ0	Moderate	Decreased metabolism of Atomoxetine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[17]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Cilostazol.	Arterial occlusive disease [BD40]	[15]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Voriconazole.	Aspergillosis [1F20]	[15]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Posaconazole.	Aspergillosis [1F20]	[15]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[15]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Atomoxetine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[15]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Linezolid	DMGFPU2	Major	Additive hypertensive effects by the combination of Atomoxetine and Linezolid.	Bacterial infection [1A00-1C4Z]	[12]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Retigabine.	Behcet disease [4A62]	[15]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Atomoxetine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[19]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Loperamide.	Bowel habit change [ME05]	[20]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Eribulin.	Breast cancer [2C60-2C6Y]	[15]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[15]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Toremifene.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Bosutinib.	Breast cancer [2C60-2C6Y]	[10]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Grepafloxacin.	Bronchitis [CA20]	[18]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Sotalol.	Cardiac arrhythmia [BC9Z]	[15]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[21]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Halothane.	Corneal disease [9A76-9A78]	[15]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Propofol.	Corneal disease [9A76-9A78]	[22]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Probucol.	Coronary atherosclerosis [BA80]	[15]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Methadone.	Cough [MD12]	[15]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Clofazimine.	Crohn disease [DD70]	[23]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Mifepristone.	Cushing syndrome [5A70]	[15]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Pasireotide.	Cushing syndrome [5A70]	[15]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Osilodrostat.	Cushing syndrome [5A70]	[10]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Sertraline.	Depression [6A70-6A7Z]	[15]
Fluoxetine	DM3PD2C	Major	Decreased metabolism of Atomoxetine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[17]
Paroxetine	DM5PVQE	Major	Decreased metabolism of Atomoxetine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[17]
Selegiline	DM6034S	Major	Additive hypertensive effects by the combination of Atomoxetine and Selegiline.	Depression [6A70-6A7Z]	[12]
Duloxetine	DM9BI7M	Moderate	Decreased metabolism of Atomoxetine caused by Duloxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[17]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Atomoxetine and Isocarboxazid.	Depression [6A70-6A7Z]	[12]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Escitalopram.	Depression [6A70-6A7Z]	[15]
Tranylcypromine	DMGB5RE	Major	Additive hypertensive effects by the combination of Atomoxetine and Tranylcypromine.	Depression [6A70-6A7Z]	[12]
Phenelzine	DMHIDUE	Major	Increased risk of hyperpyrexia by the combination of Atomoxetine and Phenelzine.	Depression [6A70-6A7Z]	[12]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Clomipramine.	Depression [6A70-6A7Z]	[15]
Mirtazapine	DML53ZJ	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Mirtazapine.	Depression [6A70-6A7Z]	[24]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Atomoxetine and Esketamine.	Depression [6A70-6A7Z]	[11]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[15]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Deutetrabenazine.	Dystonic disorder [8A02]	[25]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Ingrezza.	Dystonic disorder [8A02]	[26]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Atomoxetine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Cannabidiol.	Epileptic encephalopathy [8A62]	[10]
Diphenhydramine	DMKQTBA	Moderate	Decreased metabolism of Atomoxetine caused by Diphenhydramine mediated inhibition of CYP450 enzyme.	Episodic vestibular syndrome [AB31]	[17]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Solifenacin.	Functional bladder disorder [GC50]	[15]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Atomoxetine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[17]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Atomoxetine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[17]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Pentamidine.	Fungal infection [1F29-1F2F]	[15]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Atomoxetine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Ketoconazole.	Fungal infection [1F29-1F2F]	[15]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Atomoxetine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[17]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[15]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Procarbazine	DMIK367	Major	Increased risk of hyperpyrexia by the combination of Atomoxetine and Procarbazine.	Hodgkin lymphoma [2B30]	[12]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[27]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Atomoxetine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Atomoxetine due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Atomoxetine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Atomoxetine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[31]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Atomoxetine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[15]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Atomoxetine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[32]
Cinacalcet	DMCX0K3	Major	Decreased metabolism of Atomoxetine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[17]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Atomoxetine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[17]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Atomoxetine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[15]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[15]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Methotrexate.	Leukaemia [2A60-2B33]	[10]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Atomoxetine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[17]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Crizotinib.	Lung cancer [2C25]	[33]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Ceritinib.	Lung cancer [2C25]	[15]
Dacomitinib	DMOH8VY	Major	Decreased metabolism of Atomoxetine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Osimertinib.	Lung cancer [2C25]	[34]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Selpercatinib.	Lung cancer [2C25]	[10]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Atomoxetine caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[11]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Halofantrine.	Malaria [1F40-1F45]	[35]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Chloroquine.	Malaria [1F40-1F45]	[36]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Quinine.	Malaria [1F40-1F45]	[15]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Atomoxetine caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[17]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[37]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Idelalisib.	Mature B-cell leukaemia [2A82]	[38]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[39]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Clofarabine.	Mature B-cell lymphoma [2A85]	[40]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Vemurafenib.	Melanoma [2C30]	[15]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Panobinostat.	Multiple myeloma [2A83]	[41]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Thalidomide.	Multiple myeloma [2A83]	[11]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Siponimod.	Multiple sclerosis [8A40]	[11]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Fingolimod.	Multiple sclerosis [8A40]	[15]
Ozanimod	DMT6AM2	Major	Increased risk of hyperpyrexia by the combination of Atomoxetine and Ozanimod.	Multiple sclerosis [8A40]	[12]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Romidepsin.	Mycosis fungoides [2B01]	[15]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Atomoxetine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Atomoxetine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Droperidol.	Nausea/vomiting [MD90]	[15]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Prochlorperazine.	Nausea/vomiting [MD90]	[15]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Promethazine.	Nausea/vomiting [MD90]	[15]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Atomoxetine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[42]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Palonosetron.	Nausea/vomiting [MD90]	[15]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Granisetron.	Nausea/vomiting [MD90]	[15]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Dolasetron.	Nausea/vomiting [MD90]	[15]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Ondansetron.	Nausea/vomiting [MD90]	[15]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Atomoxetine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[17]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Entrectinib.	Non-small cell lung cancer [2C25]	[11]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Atomoxetine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[17]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Atomoxetine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[17]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Lofexidine.	Opioid use disorder [6C43]	[15]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Rucaparib.	Ovarian cancer [2C73]	[15]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Atomoxetine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[17]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Buprenorphine.	Pain [MG30-MG3Z]	[15]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Safinamide	DM0YWJC	Moderate	Decreased metabolism of Atomoxetine caused by Safinamide mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[43]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Atomoxetine and Rasagiline.	Parkinsonism [8A00]	[12]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Pimavanserin.	Parkinsonism [8A00]	[44]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Apomorphine.	Parkinsonism [8A00]	[15]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[45]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Lefamulin.	Pneumonia [CA40]	[46]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Degarelix.	Prostate cancer [2C82]	[10]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Atomoxetine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[17]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Nilutamide.	Prostate cancer [2C82]	[10]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Enzalutamide.	Prostate cancer [2C82]	[10]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Flutamide.	Prostate cancer [2C82]	[10]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Bicalutamide.	Prostate cancer [2C82]	[10]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[15]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[15]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Sorafenib.	Renal cell carcinoma [2C90]	[15]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[47]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Atomoxetine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[17]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Atomoxetine and Leflunomide.	Rheumatoid arthritis [FA20]	[15]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Atomoxetine caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[17]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Thioridazine.	Schizophrenia [6A20]	[15]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Aripiprazole.	Schizophrenia [6A20]	[11]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Paliperidone.	Schizophrenia [6A20]	[15]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Haloperidol.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Perphenazine.	Schizophrenia [6A20]	[15]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Chlorpromazine.	Schizophrenia [6A20]	[15]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Clozapine.	Schizophrenia [6A20]	[15]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Trifluoperazine.	Schizophrenia [6A20]	[15]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Risperidone.	Schizophrenia [6A20]	[15]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Amisulpride.	Schizophrenia [6A20]	[48]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Asenapine.	Schizophrenia [6A20]	[15]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[15]
Gefitinib	DM15F0X	Moderate	Decreased metabolism of Atomoxetine caused by Gefitinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[10]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[15]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[11]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[15]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[10]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Pitolisant.	Somnolence [MG42]	[15]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Atomoxetine and Naltrexone.	Substance abuse [6C40]	[49]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[15]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Atomoxetine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[15]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Lenvatinib.	Thyroid cancer [2D10]	[15]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Cabozantinib.	Thyroid cancer [2D10]	[10]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Papaverine.	Tonus and reflex abnormality [MB47]	[50]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Tizanidine.	Tonus and reflex abnormality [MB47]	[15]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Tacrolimus.	Transplant rejection [NE84]	[15]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[15]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[51]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[15]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Atomoxetine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[15]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Atomoxetine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[15]
-----------


⏷ Show the Full List of 190 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Atomoxetine 60 mg capsule	60 mg	Oral Capsule	Oral
Atomoxetine 18 mg capsule	18 mg	Oral Capsule	Oral
Atomoxetine 25 mg capsule	25 mg	Oral Capsule	Oral
Atomoxetine 40 mg capsule	40 mg	Oral Capsule	Oral
Atomoxetine 100 mg capsule	100 mg	Oral Capsule	Oral
Atomoxetine 80 mg capsule	80 mg	Oral Capsule	Oral
Atomoxetine 10 mg capsule	10 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7118).
2	Atomoxetine FDA Label
3	Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. doi: 10.1089/cap.2015.0137. Epub 2016 Feb 9.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
8	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
9	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
10	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11	Cerner Multum, Inc. "Australian Product Information.".
12	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
13	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
14	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15	Canadian Pharmacists Association.
16	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17	Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
18	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
19	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
20	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
21	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
23	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
24	Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
25	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
26	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
27	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
28	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
29	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
30	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
31	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
32	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
33	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
35	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
36	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
37	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
38	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
39	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
40	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
41	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
43	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
44	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
45	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
46	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
48	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
49	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
50	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
51	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]